May 27, 2020
St Andrews spin out company developing drug in battle against Covid-19
A new anti-viral drug developed by Pneumagen, a University of St Andrews spin out company, has had positive results in laboratory tests against Covid-19.
Pneumagen Ltd, a company focused on treating infectious disease and developing oncology treatments, has recently announced results from three separate studies into preventing coronavirus infections. The successful studies involved both treating infection and blocking new infections.
Working closely with Public Health England’s Porton facility, and separately with the University of Glasgow’s MRC Centre for Virus Research, Pneumagen has tested the activity of its technology against coronaviruses.
The mCBM technology was invented by St Andrews scientists Dr Helen Connaris, the world’s foremost expert on the use of CBMs for the treatment of disease, and Professor Garry Taylor, co-inventor of the CBM intellectual property.
Pneumagen now wants to begin clinical testing for the prevention and treatment of Covid-19.
Douglas Thomson, CEO of Pneumagen, says, “Today’s positive results from in vitro studies of our mCBMs against coronaviruses show that glycan binding has the potential to prevent and treat infection.”
Find out more about postgraduate study at the University of St Andrews.
Looking for funding for postgraduate studies? Check out the exclusive bursaries on offer from Postgrad Solutions.
Content added on 27th May 2020.
Like us on Facebook. Follow us on Twitter.